They are a newly organized blank check company. While they may pursue an initial business combination target in any business industry or geographic region, they intend to capitalize on their management team’s background and experience to identify promising opportunities in the life sciences sector. In coming together as co-sponsors of DA32, Deerfield Management, ARCH Venture Partners and Section 32 aim to leverage their complementary capabilities and networks in order to acquire, merge with and grow a promising life science technology opportunity. Individually, each of their sponsors brings deep industry expertise and a broad network across the life science technology landscape, including both private and public companies in all stages of development. Collectively, they believe that their sponsors are well positioned to help DA32 successfully identify an attractive company and equip it with the tools and connections needed to accelerate growth and become a successful publicly traded company. By combining the healthcare knowledge and sourcing networks of their sponsors, they intend to execute their strategy to bring forward a meaningful, positive impact on human health. With accelerating advancements in research technology and a boom in healthcare data and biological insights, they believe the time is ripe, and DA32 is strongly positioned to pursue opportunities in the life sciences technology industry.